95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
MINI REVIEW article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1598279
This article is part of the Research TopicAdvances in Ovarian Cancer TherapeuticsView all articles
Research progress of ferroptosis and PARP inhibitor in ovarian cancer ： action mechanism and resistance mechanism
Provisionally accepted- 1Guangdong Medical University, Zhanjiang, China
- 2Dongguan People's Hospital, Dongguan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Ovarian cancer, a gynecologic malignancy with high mortality rates, faces persistent therapeutic challenges due to acquired resistance and frequent recurrence with conventional therapies. While poly(ADP-ribose) polymerase (PARP) inhibitors have primarily transformed clinical outcomes through the synthetic lethality mechanism, their long-term efficacy remains constrained by therapeutic resistance. Ferroptosis, a novel programmed cell death modality characterized by iron-dependent lipid peroxidation, has emerged as a promising therapeutic frontier in oncology. This review summarizes the action and resistance mechanisms of ferroptosis and PARP inhibitor in ovarian cancer for the first time.
Keywords: ovarian cancer, PARP inhibitor, ferroptosis, Action mechanism, Resistance mechanism, synthetic lethality
Received: 22 Mar 2025; Accepted: 07 Apr 2025.
Copyright: © 2025 Zhang, Liu, Xiang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zhongjun Li, Guangdong Medical University, Zhanjiang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.